In the latest session, Myriad Genetics, Inc. (NASDAQ: MYGN) closed at $20.93 down -3.15% from its previous closing price of $21.61. In other words, the price has decreased by -$0.68 from its previous closing price. On the day, 1143157 shares were traded.
Ratios:
For a deeper understanding of Myriad Genetics, Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.87 and its Current Ratio is at 2.01. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.17.
On December 19, 2023, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $20.
On December 14, 2023, Guggenheim started tracking the stock assigning a Buy rating and target price of $23.Guggenheim initiated its Buy rating on December 14, 2023, with a $23 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 01 when Riggsbee Richard Bryan sold 30,000 shares for $19.09 per share. The transaction valued at 572,835 led to the insider holds 291,812 shares of the business.
Riggsbee Richard Bryan sold 30,000 shares of MYGN for $470,622 on Nov 01. The Chief Financial Officer now owns 321,812 shares after completing the transaction at $15.69 per share. On Jun 02, another insider, SPIEGELMAN DANIEL K, who serves as the Director of the company, sold 8,638 shares for $23.01 each. As a result, the insider received 198,760 and left with 40,493 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 1.94B and an Enterprise Value of 2.06B. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.28 while its Price-to-Book (P/B) ratio in mrq is 2.40. Its current Enterprise Value per Revenue stands at 2.73 whereas that against EBITDA is -10.42.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $24.21, while it has fallen to a 52-week low of $13.82. The 50-Day Moving Average of the stock is 21.08, while the 200-Day Moving Average is calculated to be 19.45.
Shares Statistics:
For the past three months, MYGN has traded an average of 652.16K shares per day and 587.65k over the past ten days. A total of 89.90M shares are outstanding, with a floating share count of 78.79M. Insiders hold about 4.14% of the company’s shares, while institutions hold 109.85% stake in the company. Shares short for MYGN as of Feb 15, 2024 were 3.7M with a Short Ratio of 5.68, compared to 3.82M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.13% and a Short% of Float of 5.71%.
Earnings Estimates
There are 12 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of $0 and a low estimate of -$0.18, while EPS last year was -$0.21. The consensus estimate for the next quarter is $0, with high estimates of $0.02 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.04 and -$0.05 for the fiscal current year, implying an average EPS of $0.01. EPS for the following year is $0.23, with 13 analysts recommending between $0.38 and $0.03.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $194.56M this quarter.It ranges from a high estimate of $199.5M to a low estimate of $190.36M. As of the current estimate, Myriad Genetics, Inc.’s year-ago sales were $181.2M, an estimated increase of 7.40% from the year-ago figure.
A total of 13 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $831.2M, while the lowest revenue estimate was $810.15M, resulting in an average revenue estimate of $825.15M. In the same quarter a year ago, actual revenue was $753.2M, up 9.60% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $894.05M in the next fiscal year. The high estimate is $914.32M and the low estimate is $860.19M. The average revenue growth estimate for next year is up 8.30% from the average revenue estimate for this year.
